Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiarrhythmic drug |
| gptkbp:approvalYear |
2009
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
C01BD07
|
| gptkbp:bioavailability |
4%
|
| gptkbp:brand |
gptkb:Multaq
|
| gptkbp:CASNumber |
141625-93-6
|
| gptkbp:contraindication |
gptkb:second-_or_third-degree_AV_block
severe heart failure QT interval prolongation liver impairment permanent atrial fibrillation |
| gptkbp:developedBy |
gptkb:Sanofi-Aventis
|
| gptkbp:drugClass |
Class III antiarrhythmic
|
| gptkbp:eliminationHalfLife |
13-19 hours
|
| gptkbp:excretion |
fecal
renal (minor) |
| gptkbp:hasBoxedWarning |
increased risk of death in patients with decompensated heart failure or permanent atrial fibrillation
|
| gptkbp:hasMolecularFormula |
C31H44N2O5S
|
| https://www.w3.org/2000/01/rdf-schema#label |
dronedarone
|
| gptkbp:KEGGID |
D08913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits potassium, sodium, and calcium channels
multichannel blocker non-competitive antiadrenergic activity |
| gptkbp:metabolism |
hepatic (CYP3A4)
|
| gptkbp:molecularWeight |
556.76 g/mol
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:proteinBinding |
>98%
|
| gptkbp:PubChem_CID |
CHEMBL1201192
181003 208902 DB04855 |
| gptkbp:relatedTo |
amiodarone
|
| gptkbp:riskFactor |
pulmonary toxicity
liver injury worsening heart failure |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea rash bradycardia increased serum creatinine |
| gptkbp:UNII |
VW5QM6VPK8
|
| gptkbp:usedFor |
gptkb:atrial_fibrillation
atrial flutter |
| gptkbp:bfsParent |
gptkb:CYP3A5
|
| gptkbp:bfsLayer |
6
|